Patent intelligence · US
US 12290597
Oral film compositions and dosage forms having precise active dissolution profiles
Oral film compositions and dosage forms having precise active dissolution profiles
Patent details — US 12290597
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 6, 2025
- Expiration
- May 1, 2045
- Applicant
- Aquestive Therapeutics, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/551, A61K31/5513, A61K9/0056
Quick answer
US 12290597 (Oral film compositions and dosage forms having precise active dissolution profiles) is held by Aquestive Therapeutics, Inc.. Status: granted. Granted May 6, 2025. Expires May 1, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aquestive Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/551, A61K31/5513, A61K9/0056, A61K9/006, A61K9/7007
More from Aquestive Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427121
Enhanced delivery epinephrine compositions
granted -
US 12403090
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 12023309
Enhanced delivery epinephrine compositions
granted -
US 11541002
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 11273131
Pharmaceutical compositions with enhanced permeation
granted -
US 11191737
Enhanced delivery epinephrine compositions
granted -
US 11129799
Dual lane coating
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 12290597?
US 12290597 (Oral film compositions and dosage forms having precise active dissolution profiles) is held by Aquestive Therapeutics, Inc.. Status: granted. Granted May 6, 2025. Expires May 1, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12290597?
Aquestive Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 12290597 expire?
Our index shows an expiration date of May 1, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.